{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"description":"Relapse/Progression criteria:\n\nCML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever \\>38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes \\>20%.\n\nAML, ALL, MDS \\>5% blasts by morphologic or flow cytometric evaluation of the BMA or appearance of extramedullary disease CLL ≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.\n\nNHL \\>25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.\n\nMM\n\n≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions","groups":[{"description":"Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo HCT\n\nCyclosporine: Given PO\n\nMycophenolate Mofetil: Given PO\n\nSirolimus: Given PO","id":"OG000","title":"Arm I (Mycophenolate Mofetil, Cyclosporine, Sirolimus)"},{"description":"Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo HCT\n\nCyclophosphamide: Given IV\n\nCyclosporine: Given PO\n\nSirolimus: Given PO","id":"OG001","title":"Arm II (Cyclosporine, Sirolimus, Cyclophosphamide)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 1 year post-HCT","title":"Number of Patients With Progression or Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"Participants"}